These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 37464793

  • 41. 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy: Central Review of Imaging and Comparison with Histopathology of Extended Lymphadenectomy.
    Esen T, Falay O, Tarim K, Armutlu A, Koseoglu E, Kilic M, Seymen H, Sarikaya AF, Kiremit MC, Balbay MD, Canda AE, Baydar DE, Kordan Y, Demirkol MO, Tilki D.
    Eur Urol Focus; 2021 Mar; 7(2):288-293. PubMed ID: 33509671
    [Abstract] [Full Text] [Related]

  • 42. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
    van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, Stricker PD.
    BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581
    [Abstract] [Full Text] [Related]

  • 43. Accuracy of 68Ga-PSMA PET-CT and PET-MRI in lymph node staging for localized prostate cancer.
    Barbosa ÁRG, Amaral BS, Lourenço DB, Bianco B, Gushiken FA, Apezzato M, Silva JF, Cunha MLD, Filippi RZ, Baroni RH, Lemos GC, Carneiro A.
    Einstein (Sao Paulo); 2022 Feb; 20():eAO6599. PubMed ID: 35584444
    [Abstract] [Full Text] [Related]

  • 44. Comparison of Bone Uptake in Bone Scan and Ga-68 PSMA PET/CT Images in Patients with Prostate Cancer.
    Acar E, Bekiş R, Polack B.
    Curr Med Imaging Rev; 2019 Feb; 15(6):589-594. PubMed ID: 32008568
    [Abstract] [Full Text] [Related]

  • 45. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by 18F-FDG PET/CT. The role of 99mTc-MDP.
    Pietrzak A, Czepczynski R, Wierzchoslawska E, Cholewinski W.
    Hell J Nucl Med; 2017 Feb; 20(3):237-240. PubMed ID: 29177262
    [Abstract] [Full Text] [Related]

  • 46. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer.
    Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, Tamaki N, Schwaiger M, Maurer T, Eiber M.
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2114-2121. PubMed ID: 27290607
    [Abstract] [Full Text] [Related]

  • 47. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.
    Franklin A, Yaxley WJ, Raveenthiran S, Coughlin G, Gianduzzo T, Kua B, McEwan L, Wong D, Delahunt B, Egevad L, Samaratunga H, Brown N, Parkinson R, Roberts MJ, Yaxley JW.
    BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
    [Abstract] [Full Text] [Related]

  • 48. Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study.
    Donswijk ML, van Leeuwen PJ, Vegt E, Cheung Z, Heijmink SWTPJ, van der Poel HG, Stokkel MPM.
    BMC Cancer; 2020 Aug 05; 20(1):723. PubMed ID: 32758168
    [Abstract] [Full Text] [Related]

  • 49. Eligibility for 177Lu-PSMA Therapy Depends on the Choice of Companion Diagnostic Tracer: A Comparison of 68Ga-PSMA-11 and 99mTc-MIP-1404 in Metastatic Castration-Resistant Prostate Cancer.
    Cook GJR, Wong WL, Sanghera B, Mangar S, Challapalli A, Bahl A, Bassett P, Leaning D, Schmidkonz C.
    J Nucl Med; 2023 Feb 05; 64(2):227-231. PubMed ID: 36302657
    [Abstract] [Full Text] [Related]

  • 50. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?
    Kulkarni SC, Sundaram PS, Padma S.
    Nucl Med Commun; 2020 Feb 05; 41(2):139-146. PubMed ID: 31714366
    [Abstract] [Full Text] [Related]

  • 51. Prostate-specific membrane antigen PET versus [99mTc]Tc-MDP bone scan for diagnosing bone metastasis in prostate cancer: a head-to-head comparative meta-analysis.
    Wang Y, Qiu Y, Yan X.
    Front Med (Lausanne); 2024 Feb 05; 11():1451565. PubMed ID: 39386742
    [Abstract] [Full Text] [Related]

  • 52. Diagnostic Performance of 99mTc-iPSMA SPECT/CT in the Initial Staging of Patients with Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer: A Comparative Analysis with 18F-PSMA-1007 PET/CT.
    Vargas-Ahumada JE, González-Rueda SD, Sinisterra-Solís FA, Casanova-Triviño P, Pitalúa-Cortés Q, Soldevilla-Gallardo I, Scavuzzo A, Jimenez-Ríos MA, García-Pérez FO.
    Cancers (Basel); 2023 Dec 13; 15(24):. PubMed ID: 38136369
    [Abstract] [Full Text] [Related]

  • 53. Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia.
    Song R, Jeet V, Sharma R, Hoyle M, Parkinson B.
    Pharmacoeconomics; 2022 Aug 13; 40(8):807-821. PubMed ID: 35761117
    [Abstract] [Full Text] [Related]

  • 54. 68Ga-PSMA PET/CT in Patients with Rising Prostatic-Specific Antigen After Definitive Treatment of Prostate Cancer: Detection Efficacy and Diagnostic accuracy.
    Hamed MAG, Basha MAA, Ahmed H, Obaya AA, Afifi AHM, Abdelbary EH.
    Acad Radiol; 2019 Apr 13; 26(4):450-460. PubMed ID: 29935970
    [Abstract] [Full Text] [Related]

  • 55. 68Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer: diagnostic sensitivity and interobserver agreement.
    Basha MAA, Hamed MAG, Hussein O, El-Diasty T, Abdelkhalek YI, Hussein YO, Alasamer AF, Mohamed HAE, Deen DSE, Tantawy EF, Metwally MI, Zaitoun MMA, Aly SA, Altohamy JI, Mohamed AEM, Afifi AHM, Harb O.
    Abdom Radiol (NY); 2019 Jul 13; 44(7):2545-2556. PubMed ID: 30963182
    [Abstract] [Full Text] [Related]

  • 56. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.
    Stabile A, Pellegrino A, Mazzone E, Cannoletta D, de Angelis M, Barletta F, Scuderi S, Cucchiara V, Gandaglia G, Raggi D, Necchi A, Karakiewicz P, Montorsi F, Briganti A.
    Eur Urol Oncol; 2022 Feb 13; 5(1):1-17. PubMed ID: 34538770
    [Abstract] [Full Text] [Related]

  • 57. PSMA SPECT/CT with 99mTc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels.
    Schmidkonz C, Goetz TI, Kuwert T, Ritt P, Prante O, Bäuerle T, Goebell P, Cordes M.
    Ann Nucl Med; 2019 Dec 13; 33(12):891-898. PubMed ID: 31502084
    [Abstract] [Full Text] [Related]

  • 58. PSMA PET Scan Era: A Changing Paradigm PSMA PET and Lymph Node Dissection for Prostate Cancer Management.
    Haxhimolla J, Kua B, Gilbourd D, Haxhimolla H.
    Semin Oncol Nurs; 2020 Aug 13; 36(4):151044. PubMed ID: 32723519
    [Abstract] [Full Text] [Related]

  • 59. Clinical parameters and nomograms for predicting lymph node metastasis detected with 68 Ga-PSMA-PET/CT in prostate cancer patients candidate to definitive radiotherapy.
    Onal C, Ozyigit G, Oymak E, Guler OC, Hurmuz P, Tilki B, Reyhan M, Tuncel M, Akyol F.
    Prostate; 2021 Jul 13; 81(10):648-656. PubMed ID: 33949694
    [Abstract] [Full Text] [Related]

  • 60. Prospective study of Na[18F]F PET/CT for cancer staging in morbidly obese patients compared with [99mTc]Tc-MDP whole-body planar, SPECT and SPECT/CT.
    Usmani S, Ahmed N, Gnanasegaran G, Al Kandari F, Marafi F, Bani-Mustafa A, Musbah A, Jassem Almashmoum M, Van den Wyngaert T.
    Acta Oncol; 2022 Oct 13; 61(10):1230-1239. PubMed ID: 35862646
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.